Denali holds gains after first human proof of concept for brain delivery tech

Denali this week reported the first clinical proof-of-concept data from its transport vehicle (TV) technology, which shuttles large molecules across the blood-brain barrier, pushing its shares to an all-time high of $69.94 on Thursday. The company held its gains to close the week at a market cap of $7.8 billion and a share price of $65.17, an increase of $9.36 (17%) from its Monday close of $55.81, before the data were announced.

“This is the first demonstration in patients that our TV technology can cross the blood-brain barrier and deliver a biotherapeutic to the brain, and opens the door to multiple applications and modalities in neurodegeneration and beyond,” said Denali CEO Ryan Watts...